DCVC Bio — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)
BoardIrena Melnikova(Executive Officer)Anna French(Director)Robert Glassman(Director)
Board seatJohn Hamer· per SEC Form D
Co-investorsMPM BioImpactQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundDCVC (Data Collective)
Durham, US
Board seatKiersten Stead· per SEC Form D · $24.5M raise · filed Dec 2021
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.